TJPC(SH:600488) Zhong Zheng Wang·2025-09-09 13:14Group 1 - The core point of the article is that Tianyao Pharmaceutical has received approval for its compound amino acid (15) dipeptide (2) injection, which enhances its product line and strengthens its competitive position in the parenteral nutrition market [1] - The compound amino acid injection is designed for patients who cannot receive nutrition orally or through the gastrointestinal tract, particularly those in moderate to severe catabolic states [1] - The projected domestic sales for the compound amino acid injection are estimated at 329 million yuan in 2023 and 234 million yuan in 2024, indicating significant market potential [1] Group 2 - Tianyao Pharmaceutical is focusing on technological innovation as a core driving force and is committed to an integrated strategy of raw materials and formulations [2] - The company aims to achieve three main goals: tackling high-value projects, optimizing the entire process system, and breaking through in multiple tracks [2] - Continuous investment in research and development, along with improvements in the R&D system and product pipeline, is expected to enhance the company's long-term development and market competitiveness [2]